Shenzhen Geno-Immune Medical Institute   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Shenzhen China (2014)

Organization Overview

First Clinical Trial
2014
NCT03050190
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shenzhen Genoimmune Medical Institute | Shenzhen Geno-Immune Medical Institute

Active Ingredients

Drugs in Phase 2 Trials (43)

4scar123 (2 trials)

4scar19 (7 trials)

4scar20 (2 trials)

4scar22 (3 trials)

4scar-276 (1 trial)

4scar38 (1 trial)

4scar79b (1 trial)

4scar-cd22/cd123/cd38/cd10/cd20/tslpr (1 trial)

4scar-fra (1 trial)

4scar-gd2 (2 trials)

4scar-psma (3 trials)

autologous lung cancer specific T cells (1 trial)

bi-4scar cd19/22 t cells (1 trial)

bi-4scar cd19/70 t cells (1 trial)

bi-4scar cd19/79b t cells (1 trial)

bi-4scar gd2/cd56 t cells (1 trial)

bi-4scar gd2/cd70 t cells (1 trial)

bi-4scar gd2/psma t cells (1 trial)

bi-4scar psma/cd70 t cells (1 trial)

car t cells (1 trial)

cd123 car-t cells (1 trial)

cd33 car-t cells (1 trial)

cd44v6-specific car gene-engineered t cells (1 trial)

cd7 car-t cell (1 trial)

cervical cancer-specific car-t cells (1 trial)

cervical cancer specific engineered immune effectors (1 trial)

cll-1 cart-t cell (1 trial)

cmv/adv /ebv/bkv specific t cells (1 trial)

gbm-specific car-igt cells (1 trial)

gd2 car t cells (1 trial)

gd2, psma and cd276 car-t cells (1 trial)

hpv specific t cells (1 trial)

lung cancer specific cytotoxic lymphocytes (1 trial)

lv-smenp-dc vaccine and antigen-specific ctls (1 trial)

muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells (1 trial)

multiple sarcoma-specific car-t cells (1 trial)

oc-eies (1 trial)

oc-igt cells (1 trial)

ovarian cancer specific cytotoxic lymphocytes (1 trial)

personalized neoantigen vaccine (2 trials)

sarcoma-specific car-t cells (1 trial)

tyf-il-2rg gene-modified autologous stem cells (1 trial)

yuva-gt-f801 (1 trial)

Drugs in Phase 1 Trials (6)

chimeric antigen receptor t cells, eps8 or wt1 peptide specific dendritic cell (1 trial)

covid-19/aapc vaccine (1 trial)

fetal mesenchymal stem cells (1 trial)

immunomodulatory dc vaccine to target dipg and gbm (1 trial)

XLCART001 (1 trial)

yuva-gt-f901 (1 trial)

Drugs in Other Trials (4)

Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo (2 trials)

lentiviral tyf-cgd-modified autologous stem cells (1 trial)

lentivirus-mediated delivery of arsa (1 trial)

tyf-ada gene-modified autologous stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 1)

Adenoviridae Infections (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Communicable Diseases (Phase 2)

Cytomegalovirus Infections (Phase 2)

Disease (Phase 1)

Epstein-Barr Virus Infections (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Hemophilia A (Phase 2)

Hemophilia B (Phase 1)

Infections (Phase 2)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Multiple Myeloma (Phase 2)

Mycoses (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neuroblastoma (Phase 2)

Opportunistic Infections (Phase 2)

Ovarian Neoplasms (Phase 2)

Papilloma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Tuberculosis (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

X-Linked Combined Immunodeficiency Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 53
  • # of Trial APIs: 53